eClinical Technology and Industy News

Persephone Biosciences Initiates VOICES Study of Gut Microbiome’s Correlation to Immune Response in COVID-19 Vaccination

Excerpt from the Press Release:

SAN DIEGO, March 11, 2021 /PRNewswire/ — Persephone Biosciences Inc., a privately held, data-driven microbiome-focused biotechnology company, today announced the initiation of the VOICES clinical study to determine the impact of gut microbiome composition and function on the immune system and efficacy of COVID-19 vaccination.

VOICES (Vaccine Observation to Include all Communities for Equitable Science) is a non-interventional, single-site study that will enroll up to 10,000 people in the U.S. being administered a COVID-19 vaccine (i.e., any vaccine currently authorized for emergency or other use in the U.S. by the Food and Drug Administration (FDA) as well as any that may be authorized for emergency or other use in the U.S. during the course of the VOICES study). The study is vaccine agnostic and will collect both blood and stool samples prior to and following subjects being vaccinated for the SARS CoV-2 virus, with the goal of identifying and determining specific gut microbiota and the metabolic processes that are involved in optimal immune response and function. Next-generation sequencing technologies will be used to examine samples from participants who subsequently contract COVID-19 after vaccination, to accurately analyze failure data and take account of and track coronavirus variants.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?